Literature DB >> 22576016

CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus.

Wakana Nakayama1, Masatoshi Jinnin, Katsunari Makino, Ikko Kajihara, Takamitsu Makino, Satoshi Fukushima, Keisuke Sakai, Yuji Inoue, Hironobu Ihn.   

Abstract

OBJECTIVE: To investigate the relationship between M2 macrophages and disease activity in SLE.
METHODS: The expression of CD163, an M2 macrophage marker, in skin specimens was evaluated by immunohistochemistry. Quantitative real-time polymerase chain reaction was performed to determine mRNA expression of CD163 in the skin section. Serum levels of soluble CD163 were measured in 20 SLE patients and 12 healthy controls with specific enzyme-linked immunosorbent assays.
RESULTS: The number of CD163-positive M2 macrophages and the mRNA levels of CD163 in the skin of SLE patients was significantly increased. SLE patients had significantly higher serum sCD163 levels than healthy controls. By analysis of the association between serum sCD163 levels and the clinical/laboratory features, we found that patients with elevated serum sCD163 levels showed significantly higher levels of anti-double-strand-DNA antibodies and higher prevalence of leukopenia than those with normal levels.
CONCLUSION: Infiltration of CD163-positive M2 macrophages was increased in SLE skin and sCD163 levels were increased in SLE sera. A systemic increase of sCD163 as well as local overexpression of CD163 in SLE patients indicate that M2 macrophages may play a role in the pathogenesis of SLE. Serum sCD163 levels may be a useful marker for disease severity in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576016     DOI: 10.1684/ejd.2012.1756

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  9 in total

Review 1.  Drug Trafficking into Macrophages via the Endocytotic Receptor CD163.

Authors:  Jonas Heilskov Graversen; Søren Kragh Moestrup
Journal:  Membranes (Basel)       Date:  2015-06-23

Review 2.  Clinical significance of sCD163 and its possible role in asthma (Review).

Authors:  Yue Zhi; Peng Gao; Xiuqin Xin; Wei Li; Lei Ji; Lin Zhang; Xueyang Zhang; Jie Zhang
Journal:  Mol Med Rep       Date:  2017-03-24       Impact factor: 2.952

3.  Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages.

Authors:  Ting Zhang; Hao Li; Kamala Vanarsa; Gabriel Gidley; Chi Chiu Mok; Michelle Petri; Ramesh Saxena; Chandra Mohan
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

Review 4.  Macrophage Polarization and Plasticity in Systemic Lupus Erythematosus.

Authors:  Mariame Mohamed Ahamada; Yang Jia; Xiaochuan Wu
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

5.  Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China.

Authors:  Guangxia Yang; Naifeng Guo; Jun Yin; Jianhua Wu
Journal:  J Int Med Res       Date:  2021-11       Impact factor: 1.671

Review 6.  The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights.

Authors:  Zoya Qaiyum; Melissa Lim; Robert D Inman
Journal:  Semin Immunopathol       Date:  2021-02-24       Impact factor: 11.759

7.  Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity.

Authors:  Gaetano Zizzo; Justus Guerrieri; Lindsay M Dittman; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

8.  CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis.

Authors:  Gregor Olmes; Maike Büttner-Herold; Fulvia Ferrazzi; Luitpold Distel; Kerstin Amann; Christoph Daniel
Journal:  Arthritis Res Ther       Date:  2016-04-18       Impact factor: 5.156

Review 9.  Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases.

Authors:  Maria K Skytthe; Jonas Heilskov Graversen; Søren K Moestrup
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.